Table I.
Patient characteristics and treatments.
| A
| |||||||
|---|---|---|---|---|---|---|---|
| Patient no. | Sex | Age (years) | Etiology | TNM stage | No. of tumors | Largest tumor | Child-Pugh |
| 1 | M | 65 | HCV | III | 2 | 22.1 | A |
| 2 | M | 58 | HBV | III | 2 | 15.9 | A |
| 3 | M | 59 | HCV | II | 1 | 6.6 | A |
| 4 | M | 64 | HBV | II | 1 | 12.4 | A |
| 5 | M | 46 | HCV | II | 9 | 30.3 | B |
| B
| ||||||
|---|---|---|---|---|---|---|
| AFP (<ng/m)
|
PIVKA-II (mAU/ml)
|
Outcome | ||||
| Patient no. | Previous treatment | Pre | Post | Pre | Post | |
| 1 | TACE | 23.7 | 56.7 | 842 | 3,109 | PD |
| 2 | TACE | 12.4 | 16.8 | 42 | 1,189 | PD |
| 3 | TACE | 27.4 | 23.2 | 53 | 67 | SD |
| 4 | TACE | 30.5 | 181.4 | 59 | 192 | PD |
| 5 | TACE | 854.1 | 660.0 | 10,707 | 30,615 | PD |
HBV, hepatitis B virus; HCV, hepatitis C virus; TACE, transcatheter hepatic arterial chemoembolization; AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonists-II; PD, progressive disease; SD, stable disease.